gdc

Lung Cancer

Early Adjuvant Treatment with Tagrisso Improves Outcomes in Patients with Non–Small-Cell Lung Cancer and EGFR Mutations
Lung Cancer
Treatment with the targeted drug Tagrisso (osimertinib) as an adjuvant therapy (used in addition to primary therapy, such as surgery or chemotherapy) significantly reduces disease recurrence in patients with localized non–small-cell lung cancer (NSCLC) and an EGFR gene mutation (alteration).
Page 1 of 9
Results 1 - 10 of 88

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country